Stage Evaluation of Cystic Duct Cancer
Cancer Research and Treatment · 2025
DOI: 10.4143/crt.2024.660 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Research and Treatment, 2025. Verfasst von Yeseul Kim und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Korea University Anam Hospital, Korea University College of Medicine, Seoul, Korea. Hauptthemen laut MEDLINE: Cystic Duct, Bile Duct Neoplasms, Gallbladder Neoplasms. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Purpose
Cystic duct cancers (CDCs) have been classified as extrahepatic bile duct cancers or gallbladder cancers (GBCs); however, it is unclear whether their clinical behavior is similar to that of distal extrahepatic bile duct cancers (DBDCs) or GBCs.Materials and Methods T category of the CDCs was classified using current T category scheme of the GBCs and DBDCs, and clinicopathological factors were compared among 38 CDCs, 345 GBCs, and 349 DBDCs. We modified Nakata’s classifications (type 1, confined within cystic duct [CD]; combined types 2-4, extension beyond CD) and compared them.
Results
No significant overall survival (OS) difference was observed between the patients with CDC, GBC, and DBDC. The T category of GBC staging was more accurate at distinguishing OS in patients with CDC than the DBDC staging. Patients with T3 CDC and GBC showed a significant OS difference when using the T category for GBC staging, while those with T1-T2 CDC and GBC showed no significant difference. In contrast, the T category of DBDC staging did not show any significant OS difference between patients with T1-T2 CDC and DBDC or T3 CDC and DBDC. Patients with type 1 CDC had significantly better OS than those with combined types.
Conclusion
Unlike GBCs and DBDCs, CDCs exhibit distinct clinicopathological characteristics. The OS is better when the CDC confines within the CD, compared to when it extends beyond it. Therefore, we propose a new T category scheme (T1, confined to CD; T2, invaded beyond CD) for better classifying CDCs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pathology, Korea University Anam Hospital, Korea University College of Medicine, Seoul, Korea.
- Department of Statistics, Korea University, Seoul, Korea.
- Department of Radiology and Research Institute of Radiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
- Department of Surgery, Seoul Soonchunhyang University Hospital, Soonchunhyang University College of Medicine, Seoul, Korea.
- Department of Pathology, Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Incheon, Korea.
- Division of Liver Transplantation and Hepatobiliary Surgery, Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Zitieren
APA
Kim, Y., Sung, Y. N., Jung, H., Lee, K. J., Yoo, D., Jun, S. Y., Cho, H., Hwang, S., Lee, W., & Hong, S. M. (2025). Stage Evaluation of Cystic Duct Cancer. Cancer Research and Treatment. https://doi.org/10.4143/crt.2024.660
Vancouver
Kim Y, Sung YN, Jung H, Lee KJ, Yoo D, Jun SY, et al. Stage Evaluation of Cystic Duct Cancer. Cancer Research and Treatment. 2025. doi:10.4143/crt.2024.660
BibTeX
@article{Kim2025,
author = {Kim, Yeseul and Sung, You-Na and Jung, Haesung and Lee, Kyung Jin and Yoo, Daegwang and Jun, Sun-Young and Cho, HyungJun and Hwang, Shin and Lee, Woohyung and Hong, Seung-Mo},
title = {Stage Evaluation of Cystic Duct Cancer},
journal = {Cancer Research and Treatment},
year = {2025},
doi = {10.4143/crt.2024.660}
}
EUVIMED